Date of this Version
The rate of new drug approvals in the US has remained essentially constant since 1950, while the costs of drug development have soared. Many commentators question the sustainability of the current model of drug development, in which large pharmaceutical companies incur markedly escalating costs to deliver the same number of products to market. This Issue Brief summarizes the problem, describes ongoing governmental efforts to influence the process, and suggests changes in regulatory science and translational medicine that may promote more successful development of safe and effective therapeutics.
This work is licensed under a Creative Commons Attribution-No Derivative Works 4.0 License.
medical technology, pharmaceuticals
View On LDI Website
Date Posted: 09 December 2016